Replies to post #1552 on Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

Speaking hypothetically, if my biggest concern re: MNTA is m-copaxone, then I would buy the company now and divest the m-copaxone "franchise."

It’s highly doubtful that the FTC would acquiesce to such a remedy; rather, the FTC would almost certainly demand that Teva divest branded Copaxone. And, for the reason stated in #msg-59680238, it’s doubtful that a third party would pay up for such an asset.